Compare SOTK & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ONCY |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.1M | 80.5M |
| IPO Year | 1995 | 2002 |
| Metric | SOTK | ONCY |
|---|---|---|
| Price | $6.29 | $0.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $8.50 | $4.16 |
| AVG Volume (30 Days) | 134.1K | ★ 1.3M |
| Earning Date | 10-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $23.41 | N/A |
| P/E Ratio | $87.21 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.40 | $0.44 |
| 52 Week High | $7.48 | $1.32 |
| Indicator | SOTK | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 29.93 |
| Support Level | $4.07 | N/A |
| Resistance Level | $7.48 | $0.89 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 47.89 | 24.48 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.